Dr. Michael J. Blaha

Dr. Michael J. Blaha MD MPH is Professor of Cardiology and Epidemiology and presently serves as the Director of Clinical Research for the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Director of the Cardiometabolic Clinic, and Program Director for the Preventive Cardiology Fellowship. His clinical interests include primary and secondary prevention of cardiovascular disease, with emphasis on early intervention in patients with advanced subclinical atherosclerosis detected with cardiac computed tomography. Dr. Blaha represents the 4th generation of physicians in his family. After earning a BS in pre-medical studies and classical civilization at the University of Notre Dame in 2001, Dr. Blaha went to Vanderbilt University where in 2006 he received his MD as well as an MPH. in clinical epidemiology and biostatistics. Dr. Blaha then completed his Internal Medicine residency in the Osler Medical Housestaff Training Program at Johns Hopkins in 2009 before completing a fellowship in Cardiology at Johns Hopkins in 2012. In 2018, Dr. Blaha received the Dr. Fred Brancati award at Johns Hopkins for excellence in mentoring. He has mentored over 30 trainees, many of which have gone on to hold prominent academic appointments. In 2021, Dr. Blaha was named to the Clarivate Highly Cited Researcher List, representing the top 1% of world’s researchers, and was first named to the Baltimore Magazine Best Doctors List. In 2022, he received the Arthur S. Agatston Cardiovascular Disease Prevention Award. Clinically, he practices as a preventive cardiologist specializing in cardiometabolic disease and in the interpretation of cardiac CT. His clinic specializes in patients with cardiometabolic disease and advanced subclinical atherosclerosis, and the focused use of an array of lifestyle and pharmacotherapies to mitigate that risk.

Dr. Blaha is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Atherosclerosis, Coronary Heart Disease, High Cholesterol, Metabolic Syndrome, and Percutaneous Coronary Intervention (PCI).

He is actively involved in clinical research, co-authoring 915 peer reviewed articles.